clinical trial · NCT06727604
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Immunovant Sciences GmbH·phase2·recruiting·n = 240
Graves' DiseaseIMVT-1402IMVT-1402Placebo
brief summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
started
Dec 17, 2024
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 22, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol